Complete pathological response (pCR) to NaCT is a surrogate marker for improved survival of patients with human epidermal growth factor 2 (HER2)-positive, triple-negative, or luminal B breast cancer.2 In addition, neo-adjuvant treatment enables assessment of sensitivity to specific drugs in vivo and allows for response-guided therapeutic strategies. Here, ERBB2 is linked to breast carcinoma.